CASI Pharmaceuticals, Inc. (CASIF) shareholders
Close on Oct 19, 2026Market cap –P/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| WEI-WU HE, Ph.D. Joint filing with Emerging Technology Partners, LLC (52.00%), ETP Global III Fund L.P. (49.30%) | 23,985,535 | 58.80% | 13D (active) amendment | May 18, 2026 |
| James Huang Joint filing with Panacea Venture Healthcare Fund II, L.P. (22.00%), Panacea Venture Healthcare Fund II GP Company, Ltd. (22.00%) and 1 more | 4,651,527 | 22.50% | 13D (active) amendment | Dec 16, 2025 |
| Chen Zhenfeng | 2,255,636 | 11.00% | 13G (passive) | Sep 30, 2025 |
| Venrock Healthcare Capital Partners III, L.P. Joint filing with VHCP Co-Investment Holdings III, LLC (9.20%), Venrock Healthcare Capital Partners EG, L.P. (9.20%) and 4 more | 1,987,259 | 9.20% | 13G (passive) amendment | Dec 31, 2025 |
| Jingbo Wang Joint filing with Kuiguang Niu (5.00%), Snow Moon Ltd (5.00%) and 9 more | 1,019,852 | 5.00% | 13D (active) amendment | Sep 30, 2025 |
| Quan Zhou Joint filing with IDG-Accel China Growth Fund III L.P. (5.90%), IDG-Accel China III Investors L.P. (5.90%) and 3 more | 992,638 | 6.40% | 13D (active) amendment | Dec 30, 2024 |
| Foresite Capital Management VI, LLC Joint filing with Foresite Capital Fund VI, L.P. (5.10%), James Tananbaum (5.10%) | 787,121 | 5.10% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CASIF | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| West Paces Advisors Inc. | 100 | 0.00% | $17 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.0% | 1 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 0 / 1 | 0 / 15 | 0M | 1M |
| Q4 2025 | 16 | 1M | 6.1% | 1 / 2 | 6 / 7 | 0M | 1M |
| Q3 2025 | 22 | 3M | 12.7% | 3 / 5 | 3 / 5 | 0M | 0M |
| Q2 2025 | 24 | 2M | 11.0% | 3 / 4 | 8 / 2 | 0M | 1M |
| Q1 2025 | 23 | 3M | 13.4% | 3 / 5 | 2 / 2 | 0M | 0M |
| Q4 2024 | 22 | 3M | 12.9% | 4 / 2 | 7 / 2 | 1M | 0M |
| Q3 2024 | 20 | 1M | 6.4% | 3 / 4 | 2 / 5 | 1M | 0M |
| Q2 2024 | 23 | 0M | 1.7% | 7 / 2 | 5 / 4 | 0M | 0M |
| Q1 2024 | 20 | 0M | 1.2% | 6 / 5 | 1 / 4 | 0M | 0M |
| Q4 2023 | 18 | 0M | 1.3% | 3 / 3 | 5 / 4 | 0M | 0M |
| Q3 2023 | 19 | 0M | 1.7% | 2 / 3 | 7 / 2 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Wei R. Gao | General Counsel | – | – | Apr 16, 2026 |
| Kun Qian | Global Controller | – | – | Apr 13, 2026 |
| Hai Huang | Global Chief Commercial Ofcr | – | – | Apr 7, 2026 |
| Chunhua Wang | Chief Operating Officer | – | – | Apr 3, 2026 |
| Alexander A. Zukiwski | Global Chief Medical Officer | – | – | Apr 3, 2026 |
| Thomas Folinsbee | Director | – | – | Apr 23, 2026 |
| Xuebo Zeng | Director | – | – | Apr 20, 2026 |
| Barbara Helene Hannelore Krebs-Pohl | Director | – | – | Mar 27, 2026 |
| Alex Wu | Director | 34,168 | 0.17% | Mar 25, 2026 |
| James Huang | Director | 4,529,956 | 22.04% | Mar 18, 2026 |
| Wei-Wu He | Director, 10% owner | 2,592,301 | 12.61% | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CASI Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Panacea Innovation Ltd Owner | Mar 15, 2024 | 171,000 | $534.19K | Mar 15, 2024 | Open Market Purchase |
| Panacea Innovation Ltd Owner | Mar 5, 2024 | 134,000 | $925.94K | Mar 5, 2024 | Open Market Purchase |
See a number that looks wrong?